Bausch Health Taps Jonathan Sadeh as Chief Medical Officer
Bausch Health Appoints Jonathan Sadeh as Executive Vice President, Chief Medical Officer and Head of R&D >BHC
Bausch Health Companies Inc. (NYSE:BHC) Is Favoured by Institutional Owners Who Hold 56% of the Company
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
PrCABTREOTM (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations From Canada's Drug Agency and Quebec's INESSS
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis
US Manufacturing Index Rises To 43, Highest Since 2020
Express News | Icahn Enterprises Discloses 9% Ownership Stake in Bausch Health Companies as of Sept 30 - Presentation
Alembic Pharmaceuticals Gets Final US FDA Nod for Diltiazem Hydrochloride Capsules
Bausch Health Companies Inc.'s (NYSE:BHC) Path To Profitability
Why Bausch Health (BHC) Is a Top Momentum Stock for the Long-Term
Bausch Health Companies Shares Are Trading Higher After RBC Capital Raised Its Price Target on the Stock From $10 to $11.
RBC on Bausch Health's Q3
Apple To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday
Bausch Health Companies Analyst Ratings
A Quick Look at Today's Ratings for Bausch Health(BHC.US), With a Forecast Between $3 to $12
RBC Lifts Price Target on Bausch Health to $11 From $10, Keeps Sector Perform Rating
Bausch Health Options Spot-On: On October 31st, 86,196 Contracts Were Traded, With 303.29K Open Interest
On October 31st ET, $Bausch Health(BHC.US)$ had active options trading, with a total trading volume of 86,196 options for the day, of which put options accounted for 79.56% of the total transactions,
Bausch Health | 10-Q: Q3 2024 Earnings Report
Toronto Stocks Drop, Canada's GDP Flat in August; Bausch Health Rises on 3Q Beat